Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2021-01-31
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
NCT06717139
Direct Discrimination of Quantum States by the Human Eye
NCT05913063
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
NCT02445313
Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration)
NCT04005443
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
NCT04739319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The quantitative IBs assessment will be done in dual mode - classic and original to the IBPAMD trial. The lesions are quantitatively assessed on one hand, by using the classic measurements of the greatest diameter, total lesions area, vessels density, fractal dimension, etc, based on the classic concept of measurements expressed in absolute values (mm, mm2 or pixels). The same lesions are quantitatively assessed by using the original IBPAMD algorithm and software (SITE-app) that introduce a new concept in the quantification of the retinal lesions, the assessment of differences reported to the baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Non-AMD eyes
No interventions assigned to this group
AMD
AMD eyes
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 years of age
* varied ethnic backgrounds (different ethnic groups have different structures of eye anatomy and we must be able to make ethnic subgroups to account for these differences)
Exclusion Criteria
* patients under 18
* pregnant (we exclude pregnant women because pregnancy often can alter eye anatomy)
* economically and educationally disadvantaged
* decision impaired
* homeless people.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Doheny Image Reading Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kenneth Marion
Program Manager - Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Narcisa
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.